The fact that Amgen, Inc.’s Humira biosimilar Amjevita (adalimumab-atto) will launch without an interchangeability designation when it is released into the US market on 31 January 2023 “has not been a barrier” for the company as it builds up to commercial availability, executive vice president of global commercial operations Murdo Gordon has said on the firm’s Q2 results call.
Lack Of Interchangeability No Barrier For Amjevita, Says Amgen Executive
Company Expects Product To Receive Designation Some Time After January Launch
While Amgen’s Amjevita (adalimumab-atto) has yet to secure an interchangeability designation, company executives appear confident this will have little impact on their Humira biosimilar’s competitiveness overall.
